Discover Ergomed’s latest whitepaper on backfilling strategies for Phase I oncology studies, offering an in-depth look at innovative dosing solutions for targeted therapies.
Learn how to optimize dose selection and response monitoring to ensure effective, timely progression to Recommended Phase 2 Dose (RP2D).
Essential for biotech and pharma companies aiming to streamline oncology drug development, this guide covers best practices for dose expansion, patient safety, and study efficiency.
Author
Erard Gilles, MD, MSc
Ergomed Medical Monitor